If you're thinking of buying shares place some limit buy orders below four cents. Don't buy at the ask.
Force the shorts to sell low so that on any news they'll have to cover at a higher price.
Avoid substantial capital gain taxes.
Some of you sold recently at four cents. Before it bounced almost 50%. Imagine how much you saved in taxes.
Sell below .06 before it goes to .20. Obama would just waste your taxes.
"AMBS" - Currently trading under a nickle. Zack's bio-tech analyst Jason Napadano says it's currently worth .20/share. Read the recent Yahoo news.
Buy and hold for six months. Due diligence.
SAN FRANCISCO and MIAMI, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has entered into an exclusive option agreement with the University of Miami to license the Bascom Palmer Eye Institute's method of use intellectual property surrounding the use of MANF and CDNF for the treatment of retinal diseases. The option agreement includes all intellectual property covering the use of the MANF-Family of proteins (MANF and CDNF) for retinal diseases including age-related macular degeneration, glaucoma, inherited retinal disorders (including Retinitis Pigmentosa), sporadic retinal disorders, other degenerative retinal disorders, and retinal injuries. This option agreement follows previously announced positive data for MANF in the S334ter Type 3 genetic mouse model of Retinitis Pigmentosa. The Company owns composition of matter patents and various composition and method of use patent applications for MANF and derivative sequences for protein therapeutic, gene therapy and certain cell therapy applications.
"The potential for MANF to treat diseases and injuries of the retina represents a tremendous commercial opportunity resulting from the strategic shift initiated last year to identify drugable orphan indications," said Gerald E. Commissiong, President & CEO of Amarantus. "As we look to complete the reprioritization of the MANF pipeline towards orphan diseases, this agreement marks a critical milestone that enables the Company to gain worldwide control of the patent prosecution process for both MANF and CDNF in this key set of indications. We believe we are now in the unique position to have control over the commercial development over both MANF and CDNF in retinal indications and are absolutely thrilled to have positioned the Company in this manner from an intellectual property standpoint in the neurotrophic factor space."
"The data generated in this set of key experiments using a highly relevant genetic mouse model of Retinitis Pigmentosa reproducibly demonstrates the neuroprotective activity of intravitreal MANF injection in protecting cellular degeneration, a key unmet need in this orphan indication," said David A. Lowe, PhD, newly appointed Board member of Amarantus whose advisory firm NeuroAssets is now developing MANF on behalf of the Company. "As we complete the clinical development plans and identify the best dosing regimen for MANF intervention to demonstrate a robust result in a well-controlled clinical trial setting in Retinitis Pigmentosa, we are pleased that we will be working with the leading ophthalmology unit in the country, with access to well characterized patients and a deep understanding of the progression of this terrible progressive degenerative retinal disorder."
The Bascom Palmer Eye Institute at the University of Miami has been ranked No. 1 nationally in ophthalmology in U.S. News & World Report's annual "Best Hospitals" rankings for 10 consecutive years. Founded in 1962, Bascom Palmer is the largest ophthalmic care, research and educational facility in the southeastern United States. Its staff treats more than 250,000 patients and performs more than 13,000 surgeries annually. At the forefront of innovation in ophthalmology for more than five decades, the institute's physicians and scientists are internationally recognized for their expertise in every eye disorder, including glaucoma, macular degeneration, diabetic retinopathy, cataracts, dry eye, eye cancers and eye diseases in children.
Second orphan indication for AMBS's patented drug , MANF, is most likely for diabetes.
Novartis is the likely partner.
Jason Napadano says AMBS is worth five times its current share price.
Follow the company on Twitter: @AmarantusBio .... 8,626 followers
Dismal retail season. Yellen won't taper until the third quarter of 2014 at the earliset. She doesn't want to get put in that position too early in her reign.
China continues to accumulat gold toward its goal of making the Yuan the world standard currency backed by gold.
Gold is oversold as are the miners.
China continues to accumulate.
Bio-tech analyst Jason Napadano says AMBS is selling at 20% of its realistic valuation currently.